Nov 8, 2019 Targeting Multiple Immune Checkpoint Proteins With Novel Small Molecular Inhibitors of Sec61-dependent Cotranslational Translocation Kezar Life Sciences, Inc
Nov 5, 2019 The Pharmacokinetic Differences Between Humans and Animals of KZR-616, a First-In-Class, Selective Immunoproteasome Inhibitor, In Two Clinical Formulations Kezar Life Sciences, Inc
Jun 13, 2019 Treatment of Systemic Lupus Erythematosus Patients with the Immunoproteasome Inhibitor KZR-616: Results from the First 2 Cohorts of an Open-label Phase 1b Dose Escalation Trial Kezar Life Sciences, Inc
Apr 10, 2019 Proteomic Profiling of a Novel Anti-Cancer Small Molecule Inhibitor of Sec61 Kezar Life Sciences, Inc.
Apr 6, 2019 KZR-616, A Selective Inhibitor of the Immunoproteasome, Attenuates the Development of Murine Lupus Nephritis Kezar Life Sciences, Inc.
Apr 2, 2019 KZR-8834: A Novel, Small Molecule Inhibitor of Sec61-Dependent Protein Secretion with Anti-Tumor Activity Kezar Life Sciences, Inc.
Apr 2, 2019 Discovery and Characterization of Novel Anti-Cancer Small Molecule Inhibitors of Sec61 Kezar Life Sciences, Inc.
Nov 6, 2018 Pharmacokinetics, Pharmacodynamics, and Their Relationship of KZR-616 in Healthy Volunteers Kezar Life Sciences, Inc.
Nov 5, 2018 Role of Epoxide Hydrolases and Cytochrome P450s on Metabolism of KZR-616, a First-in-Class Selective Inhibitor of the Immunoproteasome Kezar Life Sciences, Inc.
Nov 4, 2017 Selective Inhibition of the Immunoproteasome Subunit LMP7 is Not Sufficient for Blocking Cytokine Production or Attenuating Progression of Experimental Arthritis Kezar Life Sciences, Inc.
